March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Masimo
(NASDAQ:MASI)
Intraday
$146.85
2.37
[1.64%]
After-Hours
$146.85
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$146.85
2.37
[1.64%]
At close: Mar 28
$146.85
0
[0.00%]
After Hours: 4:30PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Masimo Stock (NASDAQ:MASI)
Masimo Stock (NASDAQ: MASI)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, March 25, 2024
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
3 days ago
Analyst Scoreboard: 5 Ratings For Masimo
Benzinga Insights
-
3 days ago
"Masimo CEO Joe Kiani Says Co May Create Joint Venture For Consumer-Business Separation; Has Been Approached By Potential Partner; Separation Could Also Take Form Of Spin Off"
Benzinga Newsdesk
-
3 days ago
Market-Moving News for March 25th
Benzinga Newsdesk
-
3 days ago
Disney To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Monday
Avi Kapoor
-
3 days ago
Patient Monitoring Device Maker Masimo Contemplates Separation of Consumer Business As Activist Investor Seeks Expanded Board Presence
Vandana Singh
-
3 days ago
BTIG Maintains Buy on Masimo, Raises Price Target to $166
Benzinga Newsdesk
-
3 days ago
Wall Street Set To Open Weak Lower As Tech Feels China Chill: Analyst Says Stay Bullish 'If And Until This Changes'
Shanthi Rexaline
-
3 days ago
Masmi shares are trading higher after the company announced it has authorized management to evaluate a proposed separation of its consumer business.
Benzinga Newsdesk
-
3 days ago
Politan Capital Management Nominates Two Independent Candidates For Masimo Board
Benzinga Newsdesk
-
3 days ago
Stifel Maintains Hold on Masimo, Raises Price Target to $148
Benzinga Newsdesk
-
3 days ago
Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Avi Kapoor
-
4 days ago
Wells Fargo Upgrades Masimo to Overweight, Raises Price Target to $160
Benzinga Newsdesk
-
4 days ago
Wall Street Journal Reported Sunday Activist Politan Plans to Nominate Two Directors at Masimo, Citing Sources
Charles Gross
-
4 days ago
Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday
Avi Kapoor
-
4 days ago
Friday, March 22, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
6 days ago
Masmi shares are trading higher after the company announced it has authorized management to evaluate a proposed separation of its consumer business. The company reaffirmed its Q1 and FY24 guidance.
Benzinga Newsdesk
-
6 days ago
Masimo Corporation Board Of Directors Authorizes Management To Evaluate Separation Of Consumer Business; Expects That Separation Will Include Its Consumer Audio And Consumer Health Products; Will Retain Its Professional Healthcare And Telehealth Products; Joe Kiani Expected To Be Named Chairman Of Newly Created Company
Benzinga Newsdesk
-
6 days ago
Masimo Corp Reaffirming Its Financial Guidance For Q1 And Fiscal Year 2024
Benzinga Newsdesk
-
6 days ago
Friday, March 15, 2024
Apple Watch 2.0? New Patents Hint At Expansion Beyond Health Tracking, New Functional Gestures After Masimo Fiasco (UPDATED)
Ananya Gairola
-
Mar 15, 2024, 1:14AM
Tuesday, February 27, 2024
Masimo Corporation Sees FY24 Adj. EPS $3.44-$3.60 Vs $3.32 Est.; Revenue 2.045B-$2.165B Vs $2.103B Est.
Benzinga Newsdesk
-
Feb 27, 2024, 5:36PM
Masimo Corporation Sees Q1 2024 Adj. EPS $0.67-$0.74 Vs $0.73 Est.; Revenue $476M-$501M Vs $514.380M Est.
Benzinga Newsdesk
-
Feb 27, 2024, 5:36PM
Masimo Q4 2023 Adj EPS $1.25 Beats $0.87 Estimate, Sales $548.90M Beat $545.73M Estimate
Benzinga Newsdesk
-
Feb 27, 2024, 5:33PM
Recap: Masimo Q4 Earnings
Benzinga Insights
-
Feb 27, 2024, 4:20PM
Earnings Scheduled For February 27, 2024
Benzinga Insights
-
Feb 27, 2024, 5:01AM
Monday, February 26, 2024
Piper Sandler Maintains Neutral on Masimo, Raises Price Target to $117
Benzinga Newsdesk
-
Feb 26, 2024, 9:43AM
A Preview Of Masimo's Earnings
Benzinga Insights
-
Feb 26, 2024, 9:01AM
Tuesday, February 20, 2024
Masimo And UCHealth Announce A Clinical Monitoring Partnership To Improve Care With Telehealth
Benzinga Newsdesk
-
Feb 20, 2024, 8:31AM
Tuesday, February 13, 2024
Masimo Announces FDA-Cleared "Over-The-Counter" Fingertip Pulse Oximeter
Benzinga Newsdesk
-
Feb 13, 2024, 9:07AM
Thursday, February 08, 2024
Masimo Announces New Peer-Reviewed Study Finds That Masimo SET Pulse Oximetry Measures Accurately Across The Skin Tone Range Even During Low Perfusion
Benzinga Newsdesk
-
Feb 8, 2024, 4:51PM
Thursday, February 01, 2024
Tim Cook Opens Up On Apple Watch Ban, Licensing Masimo Tech: 'We're Focused On Appeal'
Ananya Gairola
-
Feb 1, 2024, 8:37PM
Tuesday, January 30, 2024
Jefferies Downgrades Masimo to Hold, Raises Price Target to $121
Benzinga Newsdesk
-
Jan 30, 2024, 5:30AM
Sunday, January 28, 2024
Vision Pro Exceeds Expectations, Banned Apple Watch Feature Saves Teen And More: Top News In Appleverse This Week
Benzinga Neuro
-
Jan 28, 2024, 7:30AM
Tuesday, January 23, 2024
Tim Cook Says 'Thanks' After Banned Apple Watch Feature Saves Teen From Altitude Sickness
Ananya Gairola
-
Jan 23, 2024, 2:12AM
Monday, January 22, 2024
Samsung To Reportedly Level Up Its Health Tech Game — Plans To Challenge Apple With Noninvasive Blood Sugar Monitoring
Ananya Gairola
-
Jan 22, 2024, 8:47PM
Sunday, January 21, 2024
Apple's Move To Remove Blood Oxygen Feature In US Watches May Affect Sleep Apnea Detection, Says Mark Gurman
Ananya Gairola
-
Jan 21, 2024, 8:50PM
Saturday, January 20, 2024
Apple Watch Sidesteps Looming Ban, Cupertino Giant Outshines Samsung In Sales, Tim Cook Shows BTS Of Vision Pro: This Week In Appleverse
Benzinga Neuro
-
Jan 20, 2024, 11:02AM
Friday, January 19, 2024
Masimo CEO 'Wholeheartedly' Feels Apple Watch Users Are Better Off Without Blood Oxygen Monitoring Feature
Rounak Jain
-
Jan 19, 2024, 1:29AM
Wednesday, January 17, 2024
Apple Watch Versions Minus Blood Oxygen Feature To Go On Sale In US As Cupertino Devises Way To Sidestep Looming Ban
Ananya Gairola
-
Jan 17, 2024, 9:30PM
Bob Chapek Goes From Disney To Battling Apple: Inside New Role Announced For Former Media Executive
Chris Katje
-
Jan 17, 2024, 5:12PM
Courts Reinstate Ban On Apple Watches With Blood Oxygen Sensors
Adam Eckert
-
Jan 17, 2024, 3:37PM
U.S. Appeals Court Says Ban On U.S. Apple Watch Imports To Be Reinstated Jan. 18 After Pause
Benzinga Newsdesk
-
Jan 17, 2024, 2:38PM
Monday, January 15, 2024
Apple Dodges Import Ban In Apple Watch Patent Battle With Masimo
Piero Cingari
-
Jan 15, 2024, 1:31PM
Friday, January 12, 2024
U.S. Appeals Court Decision Upholds Earlier Patent Findings For Masimo As Apple Separately Fights Apple Watch Ban; Says Have Considered Apple's 'Remaining Arguments And Find Them Unpersuasive' In Masimo Dispute
Benzinga Newsdesk
-
Jan 12, 2024, 11:33AM
Thursday, January 11, 2024
ITC Wants Apple Ban Reinstated, Calls Apple's Arguments 'Weak And Unconvincing'
Rounak Jain
-
Jan 11, 2024, 3:43AM
Wednesday, January 10, 2024
Masimo shares are trading higher after the company raised its FY24 EPS guidance.
Benzinga Newsdesk
-
Jan 10, 2024, 3:25PM
Masimo Revises FY24 Adjusted EPS Guidance To $3.44-$3.60 From $3.00-$3.15 Versus Consensus Of $3.08
Benzinga Newsdesk
-
Jan 10, 2024, 8:13AM
Masimo Reaffirms FY24 Revenue Guidance Of $2.045B-$2.165B Versus Consensus Of $2.09B, Including Healthcare Revenue Of $1.345B-$1.385B And Non-Healthcare Revenue Of $700M-$780M
Benzinga Newsdesk
-
Jan 10, 2024, 8:11AM
Masimo Announces Preliminary FY23 Revenue Of $2.04B-$2.05B Versus Consensus Of $2.04B, Including Healthcare Revenue Of $1.272B-$1.277B And Non-Healthcare Revenue Of $769M-$774M
Benzinga Newsdesk
-
Jan 10, 2024, 8:09AM
Masimo Announces Preliminary Q4 FY23 Revenue Of $541M-$551M Versus Consensus Of $538.38M, Including Healthcare Revenue Of $336M-$341M And Non-Healthcare Revenue Of $205M-$210M
Benzinga Newsdesk
-
Jan 10, 2024, 8:07AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch